Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Original Article

P. Schmid, J. Cortes, R. Dent, H. McArthur, L. Pusztai, S. Kümmel, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, S.-A. Im, M. Untch, P.A. Fasching, M.-A. Mouret-Reynier, T. Foukakis, M. Ferreira, F. Cardoso, X. Zhou, V. Karantza, K. Tryfonidis, G. Aktan, and J. O’Shaughnessy

N Engl J Med 2024;391:1981-1991

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
11/27/2024
Course expires: 
11/28/2026

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please sign in or create an account to take the course.